1
|
Bordin DS, Voynovan IN, Sarsenbaeva AS, Zaytsev OV, Abdulkhakov RA, Bakulina NV, Bakulin IG, Osipenko MF, Livzan MA, Alekseenko SA, Tarasova LV, Tarasova GN, Bogomolov PO, Maev IV, Andreev DN, Abdulkhakov SR, Starostin BD, Bakanova NV, Kononova AG, Kolbasnikov SV, Bueverova EL, Moreira L, Megraud F, O'Morain C, Perez Nyssen O, Gisbert J. [Effectiveness of empirical Helicobacter pylori eradication therapy with furazolidone in Russia: results from the European Registry on Helicobacter pylori Management (Hp-EuReg)]. TERAPEVT ARKH 2023; 95:120-129. [PMID: 37167127 DOI: 10.26442/00403660.2023.02.202107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2023] [Accepted: 03/29/2023] [Indexed: 05/13/2023]
Abstract
BACKGROUND First-line therapy does not always provide a high level of Helicobacter pylori eradication due to the increase of H. pylori resistance to antibiotics; therefore, it remains necessary to identify the most effective rescue treatments. The purpose of this study was to evaluate the efficacy and safety of empirical H. pylori furazolidone-containing regimens. MATERIALS AND METHODS Adult H. pylori infected patients empirically treated with furazolidone-containing eradication regimens were registered in an international, prospective, multicenter non-intervention European registry on H. pylori management (Hp-EuReg). Data were collected at AEG-REDCap e-CRF from 2013 to 2021 and the quality was reviewed. Modified intention-to-treat (mITT) effectiveness analyses were performed. RESULTS Overall 106 patients received empirical furazolidone-containing therapy in Russia. Furazolidone was prescribed in a sequential scheme along with amoxicillin, clarithromycin and a proton pump inhibitor in 68 (64%) cases, triple regimens were prescribed in 28 (26%) patients and quadruple regimens in 10 (9.4%). Treatment duration of 7 days was assigned to 2 (1.9%) patients, 10-day eradication therapy in case of 80 (75%) and 14 days - in 24 (23%) patients. Furazolidone was mainly used in first- (79%) and second-line (21%) regimens. The methods used to diagnose H. pylori infection were: histology (81%), stool antigen test (64%), 13C-urea breath test (6.6%), and rapid urease test (1.9%). The mITT effectiveness of sequential therapy was 100%; 93% with the triple therapy and 75.5% with quadruple therapy. Compliance was reported in 98% of cases. Adverse events were revealed in 5.7% of patients, mostly nausea (3.8%). No serious adverse events were reported. CONCLUSION Furazolidone containing eradication regimens appear to be an effective and safe empirical therapy in Russia.
Collapse
Affiliation(s)
- D S Bordin
- Loginov Moscow Clinical Scientific Center
- Yevdokimov Moscow State University of Medicine and Dentistry
- Tver State Medical University
| | | | | | | | | | - N V Bakulina
- Mechnikov North-Western State Medical University
| | - I G Bakulin
- Mechnikov North-Western State Medical University
| | | | | | | | | | | | - P O Bogomolov
- Yevdokimov Moscow State University of Medicine and Dentistry
- Private Medical Center "Universal"
- Vladimirsky Moscow Regional Clinical Research Institute
| | - I V Maev
- Yevdokimov Moscow State University of Medicine and Dentistry
| | - D N Andreev
- Yevdokimov Moscow State University of Medicine and Dentistry
| | | | | | | | | | | | - E L Bueverova
- Sechenov First Moscow State Medical University (Sechenov University)
| | - L Moreira
- Hospital Clínic de Barcelona
- Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd)
- University of Barcelona
| | | | | | - O Perez Nyssen
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)
- Universidad Autónoma de Madrid (UAM)
| | - J Gisbert
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)
- Universidad Autónoma de Madrid (UAM)
| |
Collapse
|
2
|
Ivashkin VT, Lapina TL, Maev IV, Drapkina OM, Kozlov RS, Sheptulin AA, Trukhmanov AS, Abdulkhakov SR, Alekseeva OP, Alekseenko SA, Andreev DN, Bordin DS, Dekhnich NN, Klyaritskaya IL, Korochanskaya NV, Osipenko MF, Poluektova EA, Sarsenbaeva AS, Simanenkov VI, Tkachev AV, Ulyanin AI, Khlynov IB, Tsukanov VV. Clinical Practice Guidelines of Russian Gastroenterological Association, Scientific Society for the Clinical Study of Human Microbiome, Russian Society for the Prevention of Non-Communicable Diseases, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy for <i>H. pylori</i> Diagnostics and Treatment in Adults. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2022; 32:72-93. [DOI: 10.22416/1382-4376-2022-32-6-72-93] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/20/2023]
Abstract
Aim: bring to the attention of practitioners indications for anti-Helicobacter therapy, methods and procedure for diagnostics and eradication therapy of Н. pylori infection.Key points. Chronic gastritis caused by Н. pylori infection, including asymptomatic persons, may be considered as an indication for eradication therapy of Н. pylori as etiological therapy and opportunistic screening for gastric cancer prevention. Indications, for obligatory anti-Helicobacter therapy include peptic ulcer, gastric MALT lymphoma, early gastric cancer (EGC) with endoscopic resection. H. pylori primary diagnostics methods include 13C-urea breath test, H. pylori stool antigen lab test, rapid urease test and serological method. The serological method cannot be used after anti-Helicobacter therapy.In Russia H. pylori strains' resistance to clarithromycin does not exceed 15 % in most regional studies. The first line therapy for Н. pylori infection eradication is the standard triple therapy including a proton pump inhibitor (PPI), clarithromycin and amoxicillin, enhanced with bismuthate tripotassium dicitrate. A classic four-component therapy based on bismuthate tripotassium dicitrate or quadrotherapy without bismuth drug products which includes PPI, amoxicillin, clarithromycin and metronidazole, may be used as alternative to the first line eradication therapy. The standard triple therapy may be prescribed for 14 days only in those regions, where it has been proven to be effective. Quadrotherapy with bismuthate tripotassium dicitrate is also used as main second line therapy in case of standard triple therapy, bismuth enhanced standard triple therapy or combined therapy failure. Another second line therapy includes PPI, levofloxacin and amoxicillin, to which a bismuth-containing drug product may be added. The third line therapy is selected individually based on previously used treatment settings.Conclusion. In each case of H. pylori infection the decision for eradication therapy should be made, which is especially relevant as eradication of H. pylori has been recognized as an effective measure for the prevention of gastric cancer.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - D. S. Bordin
- Endocrinology Research Centre; Loginov Moscow Clinical Scientific Center; Tver State Medical University
| | | | | | | | | | | | | | | | | | | | | | - V. V. Tsukanov
- Research Institute for Medical Problems in the North - Division of Krasnoyarsk Scientific Centre of Siberian Branch of the RAS
| |
Collapse
|
3
|
Ivashkin VT, Lapina TL, Maev IV, Drapkina OM, Kozlov RS, Sheptulin AA, Trukhmanov AS, Abdulkhakov SR, Alekseeva OP, Alekseenko SA, Andreev DN, Bordin DS, Dekhnich NN, Klyaritskaya IL, Korochanskaya NV, Osipenko MF, Poluektova EA, Sarsenbaeva AS, Simanenkov VI, Tkachev AV, Ulyanin AI, Khlynov IB, Tsukanov VV. Clinical Practice Guidelines of Russian Gastroenterological Association, Scientific Society for the Clinical Study of Human Microbiome, Russian Society for the Prevention of Non-Communicable Diseases, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy for <i>H. pylori</i> Diagnostics and Treatment in Adults. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2022; 32:72-93. [DOI: https:/doi.org/10.22416/1382-4376-2022-32-6-72-93] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/01/2023]
Abstract
Aim: bring to the attention of practitioners indications for anti-Helicobacter therapy, methods and procedure for diagnostics and eradication therapy of Н. pylori infection.Key points. Chronic gastritis caused by Н. pylori infection, including asymptomatic persons, may be considered as an indication for eradication therapy of Н. pylori as etiological therapy and opportunistic screening for gastric cancer prevention. Indications, for obligatory anti-Helicobacter therapy include peptic ulcer, gastric MALT lymphoma, early gastric cancer (EGC) with endoscopic resection. H. pylori primary diagnostics methods include 13C-urea breath test, H. pylori stool antigen lab test, rapid urease test and serological method. The serological method cannot be used after anti-Helicobacter therapy.In Russia H. pylori strains' resistance to clarithromycin does not exceed 15 % in most regional studies. The first line therapy for Н. pylori infection eradication is the standard triple therapy including a proton pump inhibitor (PPI), clarithromycin and amoxicillin, enhanced with bismuthate tripotassium dicitrate. A classic four-component therapy based on bismuthate tripotassium dicitrate or quadrotherapy without bismuth drug products which includes PPI, amoxicillin, clarithromycin and metronidazole, may be used as alternative to the first line eradication therapy. The standard triple therapy may be prescribed for 14 days only in those regions, where it has been proven to be effective. Quadrotherapy with bismuthate tripotassium dicitrate is also used as main second line therapy in case of standard triple therapy, bismuth enhanced standard triple therapy or combined therapy failure. Another second line therapy includes PPI, levofloxacin and amoxicillin, to which a bismuth-containing drug product may be added. The third line therapy is selected individually based on previously used treatment settings.Conclusion. In each case of H. pylori infection the decision for eradication therapy should be made, which is especially relevant as eradication of H. pylori has been recognized as an effective measure for the prevention of gastric cancer.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - D. S. Bordin
- Endocrinology Research Centre; Loginov Moscow Clinical Scientific Center; Tver State Medical University
| | | | | | | | | | | | | | | | | | | | | | - V. V. Tsukanov
- Research Institute for Medical Problems in the North - Division of Krasnoyarsk Scientific Centre of Siberian Branch of the RAS
| |
Collapse
|
4
|
Ivashkin VТ, Ulyanin AI, Mayev IV, Kozlov RS, Livzan MA, Abdulkhakov SR, Alekseyeva OP, Alekseyenko SA, Bordin DS, Dekhnich NN, Korochyanskaya NV, Lapina TL, Poluektova EA, Simanenkov VI, Trukhmanov AS, Khlynov IB, Tsukanov VV, Sheptulin AA. Modern Approaches to <i>H. pylori</i> Eradication Therapy in Adults (Literature Review and Resolution of Experts Council). Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2022; 32:7-19. [DOI: https:/doi.org/10.22416/1382-4376-2022-32-6-7-19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/01/2023]
Abstract
Aim: to analyze current approaches to H. pylori eradication therapy in adults and present the materials of Experts Council held on December 9, 2022 in Moscow.General statements. H. pylori infection is the main etiological factor of gastritis, peptic ulcer, and gastric cancer. Eradication of H. pylori is recognized as a necessary measure to reduce the incidence of these diseases. The approaches to selecting an eradication regimen should be optimized to take into account epidemiological trends and achieve better treatment outcomes. The updated Maastricht VI Consensus Report presents the means to overcome the difficulties in selecting an approach to the treatment of H. pylori infection. However, eradication therapy remains challenging due to adverse events (primarily antibiotic-associated diarrhea), poor treatment tolerance and patient compliance. Eradication therapy can be optimized by supplementing treatment regimens with strain-specific probiotics that reduce adverse events, improve patient compliance and eradication rates, such as Saccharomyces boulardii CNCM I-745 strain with established efficacy.Conclusion. The inclusion of certain probiotics in eradication regimens improves treatment tolerance, reduces the risk of adverse events, improves patient compliance and eradication rates.
Collapse
Affiliation(s)
- V. Т. Ivashkin
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
| | - A. I. Ulyanin
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
| | - I. V. Mayev
- A.I. Yevdokimov Moscow State University of Medicine and Dentistry
| | | | | | - S. R. Abdulkhakov
- Gastroenterology Center of the Volga Federal District, N.A. Semashko Regional Clinical Hospital of Nizhny Novgorod; Kazan (Volga Region) Federal University
| | | | | | - D. S. Bordin
- A.I. Yevdokimov Moscow State University of Medicine and Dentistry; A.S. Loginov Moscow Clinical Scientific Center; Tver State Medical University
| | | | | | - T. L. Lapina
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
| | - E. A. Poluektova
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
| | | | - A. S. Trukhmanov
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
| | | | - V. V. Tsukanov
- Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Sciences, an autonomous branch of the Research Institute of Medical Problems of the North
| | - A. A. Sheptulin
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
| |
Collapse
|
5
|
Ivashkin VТ, Ulyanin AI, Mayev IV, Kozlov RS, Livzan MA, Abdulkhakov SR, Alekseyeva OP, Alekseyenko SA, Bordin DS, Dekhnich NN, Korochyanskaya NV, Lapina TL, Poluektova EA, Simanenkov VI, Trukhmanov AS, Khlynov IB, Tsukanov VV, Sheptulin AA. Modern Approaches to <i>H. pylori</i> Eradication Therapy in Adults (Literature Review and Resolution of Experts Council). Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2022; 32:7-19. [DOI: 10.22416/1382-4376-2022-32-6-7-19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/20/2023]
Abstract
Aim: to analyze current approaches to H. pylori eradication therapy in adults and present the materials of Experts Council held on December 9, 2022 in Moscow.General statements. H. pylori infection is the main etiological factor of gastritis, peptic ulcer, and gastric cancer. Eradication of H. pylori is recognized as a necessary measure to reduce the incidence of these diseases. The approaches to selecting an eradication regimen should be optimized to take into account epidemiological trends and achieve better treatment outcomes. The updated Maastricht VI Consensus Report presents the means to overcome the difficulties in selecting an approach to the treatment of H. pylori infection. However, eradication therapy remains challenging due to adverse events (primarily antibiotic-associated diarrhea), poor treatment tolerance and patient compliance. Eradication therapy can be optimized by supplementing treatment regimens with strain-specific probiotics that reduce adverse events, improve patient compliance and eradication rates, such as Saccharomyces boulardii CNCM I-745 strain with established efficacy.Conclusion. The inclusion of certain probiotics in eradication regimens improves treatment tolerance, reduces the risk of adverse events, improves patient compliance and eradication rates.
Collapse
Affiliation(s)
- V. Т. Ivashkin
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
| | - A. I. Ulyanin
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
| | - I. V. Mayev
- A.I. Yevdokimov Moscow State University of Medicine and Dentistry
| | | | | | - S. R. Abdulkhakov
- Gastroenterology Center of the Volga Federal District, N.A. Semashko Regional Clinical Hospital of Nizhny Novgorod; Kazan (Volga Region) Federal University
| | | | | | - D. S. Bordin
- A.I. Yevdokimov Moscow State University of Medicine and Dentistry; A.S. Loginov Moscow Clinical Scientific Center; Tver State Medical University
| | | | | | - T. L. Lapina
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
| | - E. A. Poluektova
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
| | | | - A. S. Trukhmanov
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
| | | | - V. V. Tsukanov
- Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Sciences, an autonomous branch of the Research Institute of Medical Problems of the North
| | - A. A. Sheptulin
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
| |
Collapse
|
6
|
Lazebnik LB, Bordin DS, Dekhnich NN, Kozlov RS, Livzan MA, Lyalukova EA, Luzina EV, Belova GV, Abdulkhakov RA, Abdulkhakov SR. The need to strengthen measures for the diagnosis and treatment of Helicobacter pylori infection in Russia. Memorandum. jour 2021:83-96. [DOI: 10.31146/1682-8658-ecg-187-3-83-96] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/20/2023]
Abstract
Justification The participants of the round table on diagnosis and treatment of acid - and Helicobacter-dependent diseases, held on November 20, 2020 at the XXIII congress of the Scientific Society of Gastroenterologists of Russia within the framework of the XV National Congress of Therapists (Authors) having discussed the status of the issue, decided on the need to harmonize measures and pool efforts to reduce the incidence of H. pylori infection by approaching the medical community with this Memorandum.
Collapse
Affiliation(s)
- L. B. Lazebnik
- “Moscow State University of Medicine and Density n. a. A. I. Evdokimov”
| | - D. S. Bordin
- “Moscow State University of Medicine and Density n. a. A. I. Evdokimov”; GBUZ the mcrpc them. A. S. Loginov; Tver State Medical University
| | - N. N. Dekhnich
- “Smolensk State Medical University” of the Ministry of Health of Russia
| | - R. S. Kozlov
- “Smolensk State Medical University” of the Ministry of Health of Russia
| | - M. A. Livzan
- Omsk State Medical University” of the Ministry of Health
| | | | - E. V. Luzina
- “Chitaian State Medical Academy” of the Ministry of Health of Russia
| | - G. V. Belova
- Multifocal Medicine Center of The Central Bank of Russian Federation
| | | | - S. R. Abdulkhakov
- Kazan State Medical University; Kazan (Volga region) Federal University
| |
Collapse
|
7
|
Lazebnik LB, Bordin DS, Dekhnich NN, Kozlov RS, Livzan MA, Lyalukova EA, Luzina EV, Belova GV, Abdulkhakov RA, Abdulkhakov SR. The need to strengthen measures for the diagnosis and treatment of Helicobacter pylori infection in Russia. Memorandum. jour 2021:83-96. [DOI: https:/doi.org/10.31146/1682-8658-ecg-187-3-83-96] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/01/2023]
Abstract
Justification The participants of the round table on diagnosis and treatment of acid - and Helicobacter-dependent diseases, held on November 20, 2020 at the XXIII congress of the Scientific Society of Gastroenterologists of Russia within the framework of the XV National Congress of Therapists (Authors) having discussed the status of the issue, decided on the need to harmonize measures and pool efforts to reduce the incidence of H. pylori infection by approaching the medical community with this Memorandum.
Collapse
Affiliation(s)
- L. B. Lazebnik
- “Moscow State University of Medicine and Density n. a. A. I. Evdokimov”
| | - D. S. Bordin
- “Moscow State University of Medicine and Density n. a. A. I. Evdokimov”; GBUZ the mcrpc them. A. S. Loginov; Tver State Medical University
| | - N. N. Dekhnich
- “Smolensk State Medical University” of the Ministry of Health of Russia
| | - R. S. Kozlov
- “Smolensk State Medical University” of the Ministry of Health of Russia
| | - M. A. Livzan
- Omsk State Medical University” of the Ministry of Health
| | | | - E. V. Luzina
- “Chitaian State Medical Academy” of the Ministry of Health of Russia
| | - G. V. Belova
- Multifocal Medicine Center of The Central Bank of Russian Federation
| | | | - S. R. Abdulkhakov
- Kazan State Medical University; Kazan (Volga region) Federal University
| |
Collapse
|
8
|
Iakupova AA, Abdulkhakov SR, Safin AG, Alieva IM, Oslopova JV, Abdulkhakov RA. Fecal microbiota transplantation: donor selection criteria, storage and preparation of biomaterials (review of current recommendations). TERAPEVT ARKH 2021; 93:215-221. [DOI: 10.26442/00403660.2021.02.200615] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2021] [Accepted: 04/06/2021] [Indexed: 12/12/2022]
Abstract
Fecal microbiota transplantation is a treatment method based on the introduction of donated fecal material to the recipient in order to restore the damaged composition of the intestinal microbiota. This review summarizes existing data on indications for fecal microbiota transplantation, recommendations for donor selection, processing and storage of donor biomaterial.
Collapse
|
9
|
Abdulkhakov SR, Bordin DS, Abdulkhakov RA, Safina DD, Gizdatullina AR, Gimadieva LZ, Safina GM, Ziyatdinov AI, Maturina AM, Nyssen OP, Megraud F, O'Morain C, Perez-Gisbert J. [European Registry on the management of Helicobacter pylori infection: features of diagnosis and treatment in Kazan]. TERAPEVT ARKH 2020; 92:52-59. [PMID: 33346462 DOI: 10.26442/00403660.2020.08.000758] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2020] [Indexed: 12/22/2022]
Abstract
BACKGROUND As part of an observational multicenter prospective study European Registry on the management of Helicobacter pylori infection, conducted on the initiative of the European H. pylori and Microbiota Study Group, the compliance of clinical practice in the management of patients with Helicobacter pylori infection in Kazan with clinical guidelines was assessed. MATERIALS AND METHODS The data of 437 patients included into the register by clinical sites in Kazan in 20132019 were analyzed. The methods used for the initial diagnosis of H. pylori infection and eradication control were evaluated. The frequency of various eradication therapy regimens prescription was analyzed in 379 cases. Data regarding the effectiveness of eradication therapy was analyzed in 173 patients. RESULTS The rapid urease test (44.2% of cases) and cytology/histology (60% of cases) were most often used for the initial diagnosis of H. pylori infection; however non-invasive methods such as 13C-urea breath (9.2%), serology (6.2%), H. pylori stool antigen test (2.3%) were less common. In 21.7% of patients two methods of H. pylori detection were used for primary diagnosis. The control test to evaluate the effectiveness of eradication therapy at the recommended timepoint was performed in 46.2% of patients. 13C-urea breath test (31.7%), stool PCR/stool antigen test (28.7%), rapid urease test (22.3%), cytology/histology (26.2% of cases) prevailed in the assessment of eradication rate. Standard triple therapy, including proton pump inhibitor, clarithromycin and amoxicillin was most commonly prescribed as first-line therapy (64.6% of cases). The duration of eradication therapy was 14 days in the majority of cases with pantoprazole as the most common proton pump inhibitor in standard triple therapy regimens (84.8%). The efficacy of 14-day standard triple therapy (mITT) was 87.0%. CONCLUSION The results indicate a high frequency of non-invasive methods use for assessing the effectiveness of eradication therapy; however, the overall rate of eradication efficacy assessment is low, limiting the possibility of analyzing the eradication results. The effectiveness of the most common 14-day standard triple first-line therapy in Kazan doesnt reach the recommended 90% eradication level. This could be explained by high rate of pantoprazole use, which is not an optimal proton pump inhibitor in eradication therapy regimens.
Collapse
Affiliation(s)
| | - D S Bordin
- Loginov Moscow Clinical Scientific and Practical Center.,Tver State Medical University.,Yevdokimov Moscow State University of Medicine and Dentistry
| | | | | | | | | | | | | | | | - O P Nyssen
- Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), and Universidad Autónoma de Madrid (UAM)
| | - F Megraud
- Laboratoire de Bactériologie, Hôpital Pellegrin
| | - C O'Morain
- Trinity College Dublin - Faculty of Health Sciences, Trinity College Dublin.,Dublin/IE, Faculty of Health Sciences
| | - J Perez-Gisbert
- Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), and Universidad Autónoma de Madrid (UAM)
| |
Collapse
|
10
|
Bordin DS, Embutnieks YV, Vologzhanina LG, Il'chishina TA, Voinovan IN, Sarsenbaeva AS, Alekseenko SA, Zaitsev OV, Abdulkhakov RA, Osipenko MF, Livzan MA, Tsukanov VV, Burkov SG, Bakulina NV, Dekhnich NN, Tarasova LV, Plotnikova EY, Maev IV, Kucheryavyi YA, Baryshnikova NV, Butov MA, Kolbasnikov SV, Pakhomova AL, Zhestkova TV, Baranovskii AY, Abdulkhakov SR, Ageeva EA, Lyalyukova EA, Vasyutin AV, Golubev NN, Savilova IV, Morkovkina LV, Kononova AG, Megraud F, O'Morain C, Ramas M, Nyssen OP, McNicholl AG, Gisbert JP. European Registry on the management of Helicobacter pylori infection (Hp-EuReg): analysis of 2360 patients receiving first-line therapy in Russia. TERAPEVT ARKH 2019; 90:35-42. [PMID: 30701770 DOI: 10.26442/terarkh201890235-42] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
AIM European Registry on the management of Helicobacter pylori infection («Hp-EuReg») - a multicenter prospective observational study initiated by the European Helicobacter and Microbiota Study Group, conducted in 27 European countries in order to evaluate the real clinical practice of diagnosis and treatment of H. pylori and its comparison with international recommendations. MATERIALS AND METHODS The analysis of 2360 patients entered in the register by the Russian centres of «Hp-EuReg» in 2013-2017, who were underwent 1st line eradication therapy. RESULTS The most common methods of primary diagnosis of H. pylori are histological (37.7%), rapid urease test (29.2%) and serology (29.7%). The duration of eradication therapy in 9.4% of cases was 7 days, in 65.3% - 10 days, and in 25.3% - 14 days. To control the effec- tiveness of treatment, H. pylori antigen in feces (31.3%), urea breath test (23.4%) and histological method (23.3%) were used. In 3.6% cases was used serology by mistake. In 17.3% of patients control was not carried out. The effectiveness of triple therapy with a PPI, amoxicillin, clar- ithromycin (per protocol) was 67.6%, with 7-day course, 81.1% at 10-day and 86.7% at 14-day course. Eradication rate of triple therapy with addition of bismuth (per protocol) reached 90,6% in the group receiving 10-day scheme and 93.6% in the group receiving the 14-day treatment. CONCLUSION Significant deviations of clinical practice from expert recommendations, most pronounced at the stage of monitoring the effectiveness of therapy, were noted. The suboptimal efficacy of triple therapy is shown.
Collapse
Affiliation(s)
- D S Bordin
- A.S. Loginov Moscow clinical scientific practical center of Moscow Healthcare Department , Moscow, Russia.,Tver state medical University, Ministry of health of Russia, Tver, Russia
| | - Yu V Embutnieks
- A.S. Loginov Moscow clinical scientific practical center of Moscow Healthcare Department , Moscow, Russia
| | | | | | - I N Voinovan
- A.S. Loginov Moscow clinical scientific practical center of Moscow Healthcare Department , Moscow, Russia
| | - A S Sarsenbaeva
- South Ural state medical University, Ministry of Health of Russia, Chelyabinsk, Russia
| | - S A Alekseenko
- Far Eastern State Medical University, Ministry of Health of Russia, Khabarovsk, Russia
| | - O V Zaitsev
- The First clinical medical center, Kovrov, Russia
| | - R A Abdulkhakov
- Kazan state medical University, Ministry of Health of Russia, Kazan, Russia
| | - M F Osipenko
- Novosibirsk state medical University, Ministry of Health of Russia, Novosibirsk, Russia
| | - M A Livzan
- Omsk state medical University, Ministry of health of Russia, Omsk, Russia
| | - V V Tsukanov
- Krasnoyarsk scientific center of the Siberian branch of the Russian Academy of Sciences, separat of division "Scientific research Institute of medical problems of the North", Krasnoyarsk, Russia
| | - S G Burkov
- Polyclinic №3 of Department for presidential Affairs of the Russian Federation, Moscow, Russia
| | - N V Bakulina
- I.I. Mechnikov North-Western state medical University, Ministry health of Russia, St. Petersburg, Russia
| | - N N Dekhnich
- Smolensk state medical University Ministry of health of Russia, Smolensk, Russia
| | - L V Tarasova
- Republican gastroenterology center, "Republican clinical hospital", Ministry of health of Chuvash Republic, I.N. Ulyanov state University, Cheboksary, Russia
| | - E Yu Plotnikova
- Kemerovo state medical University, Ministry health of Russia, Kemerovo, Russia
| | - I V Maev
- A.I. Evdokimov Moscow state medical dental University, Ministry of Health of Russia, Moscow, Russi
| | - Yu A Kucheryavyi
- A.I. Evdokimov Moscow state medical dental University, Ministry of Health of Russia, Moscow, Russi
| | - N V Baryshnikova
- Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia, St. Petersburg, Russia
| | - M A Butov
- I.P. Pavlov Ryazan State Medical University, Ministry of health of Russia, Ryazan, Russia
| | - S V Kolbasnikov
- Tver state medical University, Ministry of health of Russia, Tver, Russia
| | - A L Pakhomova
- V. I. Razumovsky Saratov state medical University, Ministry of health of Russia, Saratov, Russia
| | - T V Zhestkova
- I.P. Pavlov Ryazan State Medical University, Ministry of health of Russia, Ryazan, Russi
| | | | - S R Abdulkhakov
- Kazan state medical University, Ministry of Health of Russia, Kazan, Russia.,Kazan (Volga region) Federal University, Kazan, Russia
| | - E A Ageeva
- Far Eastern State Medical University, Ministry of Health of Russia, Khabarovsk, Russia
| | - E A Lyalyukova
- Omsk state medical University, Ministry of health of Russia, Omsk, Russia
| | - A V Vasyutin
- Krasnoyarsk scientific center of the Siberian branch of the Russian Academy of Sciences, separat of division "Scientific research Institute of medical problems of the North", Krasnoyarsk, Russia
| | - N N Golubev
- Polyclinic №3 of Department for presidential Affairs of the Russian Federation, Moscow, Russia
| | - I V Savilova
- I.I. Mechnikov North-Western state medical University, Ministry health of Russia, St. Petersburg, Russia
| | - L V Morkovkina
- Republican gastroenterology center, "Republican clinical hospital", Ministry of health of Chuvash Republic, I.N. Ulyanov state University, Cheboksary, Russia
| | - A G Kononova
- Tver state medical University, Ministry of health of Russia, Tver, Russia
| | - F Megraud
- Laboratoire of Bacteriology, Hospital Pellegrin, Bordeaux, France
| | - C O'Morain
- Department of Gastroenterology, Tallaght Hospital/Trinity College Dublin, Dublin, Ireland
| | - M Ramas
- Gastroenterology Unit, University Hospital «Princess», the Institute of Research in Health "Princess" (IIS-IP), Biomedical Research Centre Network of Hepatic and Digestive Diseases (CIBERehd), and Autonomous University of Madrid (UAM), Madrid, Spain
| | - O P Nyssen
- Gastroenterology Unit, University Hospital «Princess», the Institute of Research in Health "Princess" (IIS-IP), Biomedical Research Centre Network of Hepatic and Digestive Diseases (CIBERehd), and Autonomous University of Madrid (UAM), Madrid, Spain
| | - A G McNicholl
- Gastroenterology Unit, University Hospital «Princess», the Institute of Research in Health "Princess" (IIS-IP), Biomedical Research Centre Network of Hepatic and Digestive Diseases (CIBERehd), and Autonomous University of Madrid (UAM), Madrid, Spain
| | - J P Gisbert
- Gastroenterology Unit, University Hospital «Princess», the Institute of Research in Health "Princess" (IIS-IP), Biomedical Research Centre Network of Hepatic and Digestive Diseases (CIBERehd), and Autonomous University of Madrid (UAM), Madrid, Spain
| |
Collapse
|
11
|
Vinnitskaya EV, Abdulkhakov SR, Abdurakhmanov DT, Alikhanov RB, Bakulin IG, Belousova EA, Bueverov AO, Burnevitch EZ, Efanov MG, Eremina EY, Ignatova ТМ, Ilchenko LY, Karmazanovsky GG, Knyazev OV, Kulezneva YV, Lopatkina TN, Nekrasova TP, Nikitin IG, Pavlenko VV, Parfenov AI, Podymova SD, Raichelson KL, Reisis AR, Sayfutdinov RG, Skazyvaeva EV, Syutkin VE, Khomeriki SG, Haimenova TY, Sandler YG. Important problems in the diagnosis and treatment of primary sclerosing cholangitis (based on the Russian consensus on diagnosis and treatment autoimmune hepatitis. Moscow, 2018). TERAPEVT ARKH 2019; 91:9-15. [PMID: 31094167 DOI: 10.26442/00403660.2019.02.000075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The article is published based on the results of the Russian Consensus on the diagnosis and treatment of primary sclerosing cholangitis (PSC), discussed at the 44th annual Scientific Session of the CNIIG "Personalized Medicine in the Era of Standards" (March 1, 2018). The aim of the review is to highlight the current issues of classification of diagnosis and treatment of patients with PSC, which causes the greatest interest of specialists. The urgency of the problem is determined by the multivariate nature of the clinical manifestations, by often asymptomatic flow, severe prognosis, complexity of diagnosis and insufficient study of PSC, the natural course of which in some cases can be considered as a function with many variables in terms of the nature and speed of progression with numerous possible clinical outcomes. In addition to progression to portal hypertension, cirrhosis and its complications, PSC can be accompanied by clinical manifestations of obstructive jaundice, bacterial cholangitis, cholangiocarcinoma and colorectal cancer. Magnetic resonance cholangiography is the main method of radial diagnostics of PSC, which allows to obtain an image of bile ducts in an un-invasive way. The use of liver biopsy is best justified when there is a suspicion of small-diameter PSC, autoimmune cross-syndrome PSC-AIG, IgG4-sclerosing cholangitis. Currently, a drug registered to treat primary sclerosing cholangitis which can significantly change the course and prognosis of the disease does not exist. There is no unified view on the effectiveness and usefulness of ursodeoxycholic acid and its dosage in PSC. Early diagnosis and determination of the phenotype of PSC is of clinical importance. It allows to determine the tactics of treatment, detection and prevention of complications.
Collapse
Affiliation(s)
- E V Vinnitskaya
- A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow, Moscow, Russia
| | | | - D T Abdurakhmanov
- I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia
| | - R B Alikhanov
- A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow, Moscow, Russia
| | - I G Bakulin
- I.I. Mechnikov North-Western State Medical University of the Ministry of Health of the Russian Federation, Saint Petersburg, Russia
| | - E A Belousova
- M.F. Vladimirsky Moscow Regional Research Clinical Institute, Moscow, Russia
| | - A O Bueverov
- I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia
| | - E Z Burnevitch
- I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia
| | - M G Efanov
- A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow, Moscow, Russia
| | - E Yu Eremina
- Medical Institut of the N.P. Ogarev Mordovia State University, Saransk, Russia
| | - Т М Ignatova
- I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia
| | - L Yu Ilchenko
- N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - G G Karmazanovsky
- A.V. Vishnevsky Institute of Surgery of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - O V Knyazev
- A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow, Moscow, Russia
| | - Yu V Kulezneva
- A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow, Moscow, Russia
| | - T N Lopatkina
- I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia
| | - T P Nekrasova
- I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia
| | - I G Nikitin
- N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - V V Pavlenko
- Stavropol State Medical University of the Ministry of Health of the Russian Federation, Stavropol, Russia
| | - A I Parfenov
- A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow, Moscow, Russia
| | - S D Podymova
- A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow, Moscow, Russia
| | - K L Raichelson
- St Petersburg State University, Saint Petersburg, Russia
| | - A R Reisis
- Central Research Institute of Epidemiology of the Federal Service on Customers, Moscow, Russia
| | - R G Sayfutdinov
- Kazan State Medical Academy - the Branch of Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - E V Skazyvaeva
- I.I. Mechnikov North-Western State Medical University of the Ministry of Health of the Russian Federation, Saint Petersburg, Russia
| | - V E Syutkin
- N.V. Sklifosovsky Research Institute of Emergency Medical Care of the Department of Health of Moscow, Moscow, Russia
| | - S G Khomeriki
- A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow, Moscow, Russia
| | - T Yu Haimenova
- A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow, Moscow, Russia
| | - Yu G Sandler
- A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow, Moscow, Russia
| |
Collapse
|
12
|
Danilova NA, Abdulkhakov SR, Grigoryeva TV, Markelova MI, Vasilyev IY, Boulygina EA, Ardatskaya MD, Pavlenko AV, Tyakht AV, Odintsova AK, Abdulkhakov RA. Markers of dysbiosis in patients with ulcerative colitis and Crohn's disease. TERAPEVT ARKH 2019; 91:17-24. [PMID: 31094471 DOI: 10.26442/00403660.2019.04.000211] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
AIM The aim of the study was to study the taxonomic and functional composition of the gut microbiota in ulcerative colitis (UC) and Crohn's disease (CD) patients to identify key markers of dysbiosis in IBD. MATERIALS AND METHODS Fecal samples obtained from 95 IBD patients (78 UC and 17 CD) as well as 96 healthy volunteers were used for whole-genome sequencing carried out on the SOLiD 5500 W platform. Taxonomic profiling was performed by aligning the reeds, not maped on hg19, on MetaPhlAn2 reference database. Reeds were mapped using the HUNAnN2 algorithm to the ChocoPhlAn database to assess the representation of microbial metabolic pathways. Short-chain fatty acids (SCFA) level were measured in fecal samples by gas-liquid chromatographic analysis. RESULTS Changes in IBD patients gut microbiota were characterized by an increase in the representation of Proteobacteria and Bacteroidetes phyla bacteria and decrease in the number of Firmicutes phylum bacteria and Euryarchaeota phylum archaea; a decrease in the alpha-diversity index, relative representation of butyrate-producing, hydrogen-utilizing bacteria, and Methanobrevibacter smithii; increase in the relative representation of Ruminococcus gnavus in UC and CD patients and Akkermansia muciniphila in CD patients. Reduction of Butyryl-CoA: acetate CoA transferase gene relative representation in CD patients, decrease of absolute content of SCFA total number as well as particular SCFAs and main SCFAs ratio in IBD patients may indicate inhibition of functional activity and number of anaerobic microflora and/or an change in SCFA utilization by colonocytes. CONCLUSION the revealed changes can be considered as typical signs of dysbiosis in IBD patients and can be used as potential targets for IBD patients personalized treatment development.
Collapse
Affiliation(s)
| | - S R Abdulkhakov
- Kazan Federal University, Kazan, Russia.,Kazan State Medical University of the Ministry of Health of the Russian Federation, Kazan, Russia
| | | | | | | | | | - M D Ardatskaya
- Central State Medical Academy of Administrative Department of the President of the Russian Federation, Moscow, Russia
| | - A V Pavlenko
- Federal Research and Clinical Centre of Physical-Chemical Medicine of the Federal Medical and Biological Agency, Moscow, Russia
| | - A V Tyakht
- Institute of Gene Biology of RAS, Moscow, Russi
| | - A Kh Odintsova
- Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan, Kazan, Russia
| | - R A Abdulkhakov
- Kazan State Medical University of the Ministry of Health of the Russian Federation, Kazan, Russia
| |
Collapse
|
13
|
Khatkov IE, Maev IV, Abdulkhakov SR, Alekseenko SA, Alikhanov RB, Bakulin IG, Bakulina NV, Baranovskiy AY, Beloborodova EV, Belousova EA, Voskanyan SE, Vinokurova LV, Grinevich VB, Darvin VV, Dubtsova EA, Dyuzheva TG, Egorov VI, Efanov MG, Izrailov RE, Korobka VL, Kotiv BN, Kokhanenko NY, Kucheryavyy YA, Livzan MA, Lyadov VK, Nikolskaya KA, Osipenko MF, Pasechnikov VD, Plotnikova EY, Sablin OA, Simanenkov VI, Tsvirkun VV, Tsukanov VV, Shabunin AV, Bordin DS. Russian consensus on exo- and endocrine pancreatic insufficiency after surgical treatment. TERAPEVT ARKH 2019; 90:13-26. [PMID: 30701935 DOI: 10.26442/terarkh201890813-26] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
The Russian consensus on exo- and endocrine pancreatic insufficiency after surgical treatment was prepared on the initiative of the Russian "Pancreatic Club" on the Delphi method. His goal was to clarify and consolidate the opinions of specialists on the most relevant issues of diagnosis and treatment of exo- and endocrine insufficiency after surgical interventions on the pancreas. An interdisciplinary approach is provided by the participation of leading gastroenterologists and surgeons.
Collapse
Affiliation(s)
- I E Khatkov
- A.S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department, Moscow, Russia.,A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia
| | - I V Maev
- A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia
| | - S R Abdulkhakov
- Kazan State Medical University, Ministry of Health of Russia, Kazan, Russia
| | - S A Alekseenko
- The Far Eastern State Medical University, Ministry of Health of Russia, Khabarovsk, Russia
| | - R B Alikhanov
- A.S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department, Moscow, Russia
| | - I G Bakulin
- I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint-Petersburg, Russia
| | - N V Bakulina
- I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint-Petersburg, Russia
| | | | - E V Beloborodova
- Siberian State Medical University, Ministry of Health of Russia, Tomsk, Russia
| | - E A Belousova
- M.F. Vladimirskiy Moscow Regional Research and Clinical Institute, Moscow, Russia
| | - S E Voskanyan
- A.I. Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, Moscow, Russia
| | - L V Vinokurova
- A.S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department, Moscow, Russia
| | - V B Grinevich
- S.M. Kirov Military Medical Academy, Ministry of Defence of Russia, Saint-Petersburg, Russia
| | - V V Darvin
- Medical Institute of Surgut State University, Surgut, Russia
| | - E A Dubtsova
- A.S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department, Moscow, Russia
| | - T G Dyuzheva
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia, Moscow, Russia
| | - V I Egorov
- City Clinical Hospital named after the Bakhrushin Brothers, Moscow, Russia
| | - M G Efanov
- A.S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department, Moscow, Russia
| | - R E Izrailov
- A.S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department, Moscow, Russia
| | - V L Korobka
- Rostov State Medical University, Ministry of Health of Russia, Rostov-on-Don, Russia
| | - B N Kotiv
- S.M. Kirov Military Medical Academy, Ministry of Defence of Russia, Saint-Petersburg, Russia
| | - N Yu Kokhanenko
- Saint-Petersburg State Pediatric Medical University, Ministry of Health of Russia, Saint-Petersburg, Russia
| | - Yu A Kucheryavyy
- A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia
| | - M A Livzan
- Omsk State Medical University, Ministry of Health of Russia, Omsk, Russia
| | - V K Lyadov
- Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia, Moscow, Russia
| | - K A Nikolskaya
- A.S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department, Moscow, Russia
| | - M F Osipenko
- Novosibirsk State Medical University, Ministry of Health of Russia, Novosibirsk, Russia
| | - V D Pasechnikov
- Stavropol State Medical University, Ministry of Health of Russia, Stavropol, Russia
| | - E Yu Plotnikova
- Kemerovo State Medical University, Ministry of Health of Russia, Kemerovo, Russia
| | - O A Sablin
- A.M. Nikiforov All-Russian Center for Emergency and Radiation Medicine, Russian Ministry for Emergency Situations, Saint-Petersburg, Russia
| | - V I Simanenkov
- I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint-Petersburg, Russia
| | - V V Tsvirkun
- A.S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department, Moscow, Russia
| | - V V Tsukanov
- Krasnoyarsk Scientific Center of Siberian Branch in Russian Academy of Sciences, Krasnoyarsk, Russia
| | - A V Shabunin
- S.P. Botkin City Hospital, Moscow Healthcare Department, Moscow, Russia
| | - D S Bordin
- A.S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department, Moscow, Russia.,Tver State Medical University, Ministry of Health of Russia, Tver, Russia
| |
Collapse
|
14
|
Akhtereeva AR, Morozova LG, Faizullina RA, Ivanovskaya KA, Pozdeev OK, Valeeva IK, Abdulkhakov SR. Antibiotic Susceptibility Assessment of Helicobacter pylori Isolates by Disk-Diffusion Method. BioNanoSci 2018. [DOI: 10.1007/s12668-018-0527-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
15
|
Lopukhov LV, Laikov AV, Romanova VA, Gatina DZ, Lopukhov VL, Abdulkhakov SR, Zaitseva TA, Medvedeva SN, Gnuchikh EV, Salafutdinov II, Grigoryeva TV. LC-MS Method Development for Simultaneous Determination of Trans-3′-hydroxycotinine and Three Mercapturic Acids in Urine. BioNanoSci 2018. [DOI: 10.1007/s12668-018-0528-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
16
|
Bordin DS, Plavnik RG, Nevmerzhitskiy VI, Butorova LI, Abdulkhakov RA, Abdulkhakov SR, Voinovan IN, Embutnieks IV. Prevalence of Helicobacter pylori among medical workers in Moscow and Kazan according to ¹³С-urease breath test. ACTA ACUST UNITED AC 2018. [DOI: 10.18786/2072-0505-2018-46-1-40-49] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
17
|
Abdulkhakov SR, Bagnenko SF, Bordin DS, Bredenoord AJ, Burganova GR, Valitova ER, Vasilevskiy DI, Gasanov AM, Isakov VA, Kaybysheva VO, Klyaritskaya IL, Krivoy VV, Lyubchenko ME, Morozov SV, Nikonov EL, Pasechnikov VD, Petrikov SS, Sazhin AV, Smirnov AA, Fedorov ED, Khat'kov IE, Shapoval'yants SG. Draft guidelines on high-resolution oesophageal manometry.The uniform protocol of the conclusion. Dok gastroenterol 2018. [DOI: 10.17116/dokgastro2018703191] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
18
|
Abdulkhakov SR, Bagnenko SF, Barkalova EV, Bordin DS, Bredenoord AJ, Burganova GR, Valitova ER, Vasilevskiy DI, Gasanov AM, Isakov VA, Kaybysheva VO, Klyaritskaya IL, Krivoy VV, Kucheryavyy YA, Lyubchenko ME, Morozov SV, Nikonov EL, Ovsepyan MA, Pasechnikov VD, Petrikov SS, Sazhin AV, Smirnov AA, Fedorov ED, Khat'kov IE, Shapoval'yants SG. Resolution of the expert panel on the 'First Russian high-resolution esophageal manometry Consensus'. Dok gastroenterol 2018. [DOI: 10.17116/dokgastro20187150-54] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
19
|
Khatkov IE, Maev IV, Bordin DS, Kucheryavyi YA, Abdulkhakov SR, Alekseenko SA, Alieva EI, Alikhanov RB, Bakulin IG, Baranovsky AY, Beloborodova EV, Belousova EA, Buriev IM, Bystrovskaya EV, Vertyankin SV, Vinokurova LV, Galperin EI, Gorelov AV, Grinevich VB, Danilov MV, Darvin VV, Dubtsova EA, Dyuzheva TG, Egorov VI, Efanov MG, Zakharova NV, Zagainov VE, Ivashkin VT, Izrailov RE, Korochanskaya NV, Kornienko EA, Korobka VL, Kokhanenko NY, Livzan MA, Loranskaya ID, Nikolskaya KA, Osipenko MF, Okhlobystin AV, Pasechnikov VD, Plotnikova EY, Polyakova SI, Sablin OA, Simanenkov VI, Ursova NI, Tsvirkun VV, Tsukanov VV, Shabunin AV. The Russian consensus on the diagnosis and treatment of chronic pancreatitis: Enzyme replacement therapy. TERAPEVT ARKH 2017; 89:80-87. [PMID: 28914856 DOI: 10.17116/terarkh201789880-87] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/01/2023]
Abstract
Pancreatology Club Professional Medical Community, 1A.S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department, Moscow; 2A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow; 3Kazan State Medical University, Ministry of Health of Russia, Kazan; 4Kazan (Volga) Federal University, Kazan; 5Far Eastern State Medical University, Ministry of Health of Russia, Khabarovsk; 6Morozov City Children’s Clinical Hospital, Moscow Healthcare Department, Moscow; 7I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint Petersburg; 8Siberian State Medical University, Ministry of Health of Russia, Tomsk; 9M.F. Vladimirsky Moscow Regional Research Clinical Institute, Moscow; 10Maimonides State Classical Academy, Moscow; 11V.I. Razumovsky State Medical University, Ministry of Health of Russia, Saratov; 12I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow; 13S.M. Kirov Military Medical Academy, Ministry of Defense of Russia, Saint Petersburg; 14Surgut State Medical University, Ministry of Health of Russia, Surgut; 15City Clinical Hospital Five, Moscow Healthcare Department, Moscow; 16Nizhny Novgorod Medical Academy, Ministry of Health of Russia, Nizhny Novgorod; 17Territorial Clinical Hospital Two, Ministry of Health of the Krasnodar Territory, Krasnodar; 18Saint Petersburg State Pediatric Medical University, Ministry of Health of Russia, Saint Petersburg; 19Rostov State Medical University, Ministry of Health of Russia, Rostov-on-Don; 20Omsk Medical University, Ministry of Health of Russia, Omsk; 21Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia, Moscow; 22Novosibirsk State Medical University, Ministry of Health of Russia, Novosibirsk; 23Stavropol State Medical University, Ministry of Health of Russia, Stavropol; 24Kemerovo State Medical University, Ministry of Health of Russia, Kemerovo; 25N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow; 26A.M. Nikiforov All-Russian Center of Emergency and Radiation Medicine, Russian Ministry for Civil Defense, Emergencies and Elimination of Consequences of Natural Disasters, Saint Petersburg; 27Research Institute for Medical Problems of the North, Siberian Branch, Russian Academy of Sciences, Krasnoyarsk; 28S.P. Botkin City Clinical Hospital, Moscow Healthcare Department, Moscow; 29Tver State Medical University, Ministry of Health of Russia, Tver The Russian consensus on the diagnosis and treatment of chronic pancreatitis has been prepared on the initiative of the Russian Pancreatology Club to clarify and consolidate the opinions of Russian specialists (gastroenterologists, surgeons, and pediatricians) on the most significant problems of diagnosis and treatment of chronic pancreatitis. This article continues a series of publications explaining the most significant interdisciplinary consensus statements and deals with enzyme replacement therapy.
Collapse
|
20
|
Khatkov IE, Maev IV, Abdulkhakov SR, Alekseenko SA, Alieva EI, Alikhanov RB, Bakulin IG, Baranovsky AY, Beloborodova EV, Belousova EA, Buriev IM, Bystrovskaya EV, Vertyankin SV, Vinokurova LV, Galperin EI, Gorelov AV, Grinevich VB, Danilov MV, Darvin VV, Dubtsova EA, Dyuzheva TG, Egorov VI, Efanov MG, Zakharova NV, Zagainov VE, Ivashkin VT, Izrailov RE, Korochanskaya NV, Kornienko EA, Korobka VL, Kokhanenko NY, Kucheryavyi YA, Livzan MA, Loranskaya ID, Nikolskaya KA, Osipenko MF, Okhlobystin AV, Pasechnikov VD, Plotnikova EY, Polyakova SI, Sablin OA, Simanenkov VI, Ursova NI, Tsvirkun VV, Tsukanov VV, Shabunin AV, Bordin DS. The Russian consensus on the diagnosis and treatment of chronic pancreatitis. TERAPEVT ARKH 2017; 89:105-113. [DOI: 10.17116/terarkh2017892105-113] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/20/2023]
Abstract
1Moscow Clinical Research and Practical Center, Moscow Healthcare Department, Moscow; 2A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow; 3Kazan State Medical University, Kazan; 4Kazan (Volga) Federal University, Kazan; 5Far Eastern State Medical University, Ministry of Health of Russia, Khabarovsk; 6Morozov City Children’s Clinical Hospital, Moscow Healthcare Department, Moscow; 7I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint Petersburg; 8Siberian State Medical University, Ministry of Health of Russia, Tomsk; 9M.F. Vladimirsky Moscow Regional Research Clinical Institute, Moscow; 10Maimonides State Classical Academy, Moscow; 11V.I. Razumovsky Saratov State Medical University, Saratov; 12I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow; 13S.M. Kirov Military Medical Academy, Ministry of Defense of the Russian Federation, Saint Petersburg; 14Surgut State Medical University, Ministry of Health of Russia, Surgut; 15City Clinical Hospital Five, Moscow Healthcare Department, Moscow; 16Nizhny Novgorod Medical Academy, Ministry of Health of Russia, Nizhny Novgorod; 17Territorial Clinical Hospital Two, Ministry of Health of the Krasnodar Territory, Krasnodar; 18Saint Petersburg State Pediatric Medical University, Ministry of Health of Russia, Saint Petersburg; 19Rostov State Medical University, Ministry of Health of Russia, Rostov-on-Don; 20Omsk Medical University, Ministry of Health of Russia, Omsk; 21Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia, Moscow; 22Novosibirsk State Medical University, Novosibirsk; 23Stavropol State Medical University, Ministry of Health of Russia, Stavropol; 24Kemerovo State Medical University, Ministry of Health of Russia, Kemerovo; 25N.I. Pirogov Russian Research Medical University, Ministry of Health of Russia, Moscow; 26A.M. Nikiforov All-Russian Center of Emergency and Radiation Medicine, Ministry of Emergency Situations of Russia, Saint Petersburg; 27Federal Research Center, Krasnoyarsk Research Center, Siberian Branch, Russian Academy of Sciences, Research Institute of Medical Problems of the North, Krasnoyarsk; 28S.P. Botkin City Clinical Hospital, Moscow Healthcare Department, Moscow; 29Tver State Medical University, Ministry of Health of Russia, Tver The Russian consensus (a consensus document) on the diagnosis and treatment of chronic pancreatitis has been prepared on the initiative of the Russian «Pancreatic Club» under the Delphi system. Its aim was to identify and consolidate the opinions of Russian experts on the most topical issues of the diagnosis and treatment of chronic pancreatitis. The interdisciplinary approach involved the participation of leading gastroenterologists, surgeons, and pediatricians.
Collapse
|
21
|
Vyshtakalyuk AB, Nazarov NG, Zobov VV, Abdulkhakov SR, Minnekhanova OA, Semenov VE, Galyametdinova IV, Cherepnev GV, Reznik VS. Evaluation of the Hepatoprotective Effect of L-Ascorbate 1-(2-Hydroxyethyl)-4,6-Dimethyl-1,2-Dihydropyrimidine-2-One Upon Exposure to Carbon Tetrachloride. Bull Exp Biol Med 2017; 162:340-342. [DOI: 10.1007/s10517-017-3610-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2015] [Indexed: 10/20/2022]
|
22
|
Bordin DS, Yanova OB, Abdulkhakov RA, Tsukanov VV, Livzan MA, Burkov SG, Zakharova NV, Plotnikova EY, Osipenko MF, Tarasova LV, Maev IV, Kucheryavyi YA, Butov MA, Sablin OA, Kolbasnikov SV, Voinovan IN, Abdulkhakov SR, Vasyutin AV, Lyalyukova EA, Golubev NN, Savilova IV, Grigoryeva LV, Kononova AG, O'Morain C, Ramas M, Mcnicholl AG, Gisbert JP. European Registry on the management of Helicobacter pylori infection (Hp-EuReg protocol): The first results of Russian centers. TERAPEVT ARKH 2016; 88:33. [PMID: 27030181 DOI: 10.17116/terarkh201688233-38] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/01/2023]
|
23
|
Bordin DS, Yanova OB, Abdulkhakov RA, Tsukanov VV, Livzan MA, Burkov SG, Zakharova NV, Plotnikova EY, Osipenko MF, Tarasova LV, Maev IV, Kucheryavyi YA, Butov MA, Sablin OA, Kolbasnikov SV, Voinovan IN, Abdulkhakov SR, Vasyutin AV, Lyalyukova EA, Golubev NN, Savilova IV, Grigoryeva LV, Kononova AG, O’Morain C, Ramas M, Mcnicholl AG, Gisbert JP. European Registry on the management of Helicobacter pylori infection (Hp-EuReg protocol): The first results of Russian Centers. Dok gastroenterol 2016; 5:9. [DOI: 10.17116/dokgastro2016519-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/20/2023]
|
24
|
Safina DD, Abdulkhakov SR, Abdulkhakov RA. ERADICATION THERAPY OF HELICOBACTER PYLORI: PRESENT AND FUTURE. Eksp Klin Gastroenterol 2016:84-93. [PMID: 29889451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Recently the rate of successful H. pylod eradication while using existing treatment regimens continues to decline, primarily due to the appearance of antibiotic-resistant strains of the microorganism. Recent studies confirm the fact that the standard triple therapy becomes ineffective method of H. pylori eradication, due to the increase of drug-resistant strains of.H. pylon. H. pylori resistance level to antibacterial agents is not the same in different countries, as well as in certain regions within the same country. Thus, studing the regional features of H. pylori resistance to certain antibiotics with subsequent development of eradication regimens that are effective in particular region becomes extremely actual. Still bismuth containing quadruple therapy remains an effective method of H. pylori eradication, allowing to achieve good results. In recent years, several alternative schemes of H. pylori eradication were proposed, such as sequential, concomitant, hybrid therapy including three antimicrobial agents. Currently; these regimens allow to achieve quite high H. pyloneradication level.
Collapse
|
25
|
Bruslik NL, Akhatova DR, Toimentseva AA, Abdulkhakov SR, Ilyinskaya ON, Yarullina DR. [Estimation of Probiotic Lactobacilli Drug Resistance]. Antibiot Khimioter 2015; 60:6-13. [PMID: 26415377] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
An actual problem of analysis of probiotic lactobacilli resistance to antibiotics and other drugs used in the treatment of gastro-intestinal disturbances has been for the first time solved. The levels of resistance of 19 strains of Lactobacillus (14 strains of L. fermentum, 4 strains of L.plantarum and 1 strain of L.rhamnosus) isolated from commercial probiotics and sour milk products to 14 antibiotics of various nature, i.e. β-lactams, aminoglycosides, macrolides, clindamycin, vancomycin, rifampicin, ciprofloxacin, tetracycline and chloramphenicol were determined. All the isolates were practically susceptible to the drugs of the first line antihelicobacterial therapy, i.e. amoxicillin and clarithromycin, that makes inexpedient the parallel use of the probiotics containing the above lactobacilli in the treatment of gastritis and gastric ulcer, despite the lactobacilli antagonism with respect to Helicobacter pylory. Lactobacilli are as well resistant to mesalazin and can be used for correction of dysbiosis in inflammatory affections of the intestine.
Collapse
|
26
|
Mukhamedyarov MA, Rizvanov AA, Safiullov ZZ, Izmailov AA, Sharifullina GA, Solovieva VV, Fedotova VY, Salafutdinov II, Cherenkova EE, Bashirov FV, Kaligin MS, Abdulkhakov SR, Shmarov MM, Logunov DY, Naroditsky BS, Kiyasov AP, Zefirov AL, Islamov RR. Analysis of the efficiency of gene-cell therapy in transgenic mice with amyotrophic lateral sclerosis phenotype. Bull Exp Biol Med 2013; 154:558-61. [PMID: 23486603 DOI: 10.1007/s10517-013-1999-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Amyotrophic lateral sclerosis is a neurodegenerative disease characterized by progressive death of cerebral and spinal motorneurons. Using behavioral tests we studied the efficiency of gene-cell therapy in SOD1 G93A transgenic mice receiving xenotransplantation of human umbilical cord blood mononuclear cells genetically modified with adenoviral vectors encoding vascular endothelial growth factor (VEGF) and reporter green fluorescent protein (EGFP) genes. The cells were transplanted to mice on week 27 of life (preclinical stage of the disease). Behavioral tests (open field, grip strength test) showed that transplantation of umbilical cord blood mononuclear cells expressing VEGF significantly improved the parameters of motor and explorative activity, grip strength, and animal survival. Thus, gene-cell therapy based on genetically modified mononuclear cells expressing VEGF can be efficient for the treatment of amyotrophic lateral sclerosis.
Collapse
Affiliation(s)
- M A Mukhamedyarov
- Kazan State Medical University, Ministry of Health Care of the Russian Federation, Moscow, Russia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Safina DD, Abdulkhakov RA, Abdulkhakov SR, Odintsova AK, Cheremina NA. [Clinical case of a combination of ulcerative colitis and alopecia areata]. Eksp Klin Gastroenterol 2013:92-96. [PMID: 24933997] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Extraintestinal manifestations of inflammatory bowel diseases (IBD) are common in both ulcerative colitis and Crohn's disease. Dermatological manifestations have been reported in one-third of all extraintestinal manifestations of IBD. Erythema nodosum and pyoderma gangrenosum are the most frequently described in the literature. There is no data on the development of alopecia as a cutaneous manifestation of IBD in most of studies. A clinical case of combination of ulcerative colitis and alopecia in young woman is presented in the article. There are several possible causes of alopecia in patients with IBD, such as nutritional deficiencies, side effects of medications or autoimmune alopecia. Most often there is no correlation between the severity of clinical bowel manifestations and other organs involvement, and response to therapy. So the combination of alopecia with IBD, in particular ulcerative colitis, confirms the importance of autoimmune mechanisms in genesis of these diseases.
Collapse
|
28
|
Abstract
We evaluated the relationship between pathological changes in the liver and the state of intestinal microflora in rats with experimental dysbiosis. Changes in the intestinal microflora were accompanied by alteration of the morphological structure in the liver. Enhanced proliferation of Ito cells served as an indirect evidence of damage to the liver. Ito cells did not undergo transformation into myofibroblasts that excluded the possibility of fibrosis.
Collapse
|
29
|
Salakhov IM, Sozinov AS, Abdulkhakov SR, Kiyasov AP, Lysova NL, Yakovlev MY. A single endotoxin aggression causes dose-dependent reversible activation of rat liver ito cells without their transdifferentiation into myofibroblasts. Bull Exp Biol Med 2000. [DOI: 10.1007/bf02682049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
30
|
Salakhov IM, Sozinov AS, Abdulkhakov SR, Kiyasov AP, Lysova NL, Yakovlev MY. A single endotoxin aggression causes dose-dependent reversible activation of rat liver Ito cells without their transdifferentiation into myofibroblasts. Bull Exp Biol Med 2000; 130:997-1000. [PMID: 11177304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2000] [Indexed: 02/18/2023]
Abstract
The effect of Gram-negative bacterial lipopolysaccharide on rat hepatocytes and sinusoidal cells was studied. The damage and regeneration potential of the liver were evaluated by activation of perisinusoidal Ito cells and proliferative activity of liver cells. Compensatory and repair reactions in the liver induced by lipopolysaccharide manifested by proliferation of liver cells and reversible activation of Ito cells without their transdifferentiation into myofibroblasts.
Collapse
Affiliation(s)
- I M Salakhov
- Institute of General and Clinical Pathology, Clinical Diagnostic Society, Moscow
| | | | | | | | | | | |
Collapse
|
31
|
Salakhov IM, Sozinov AS, Abdulkhakov SR, Kiyasov AP, Lysova NL, Yakovlev MY. Bull Exp Biol Med 2000; 130:997-1000. [DOI: 10.1023/a:1002830310971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|